Moderna and Merck said Wednesday their experimental mRNA cancer vaccine successfully reduced recurrence of melanoma, and ...

If ongoing studies in other cancers produce similar results, the technology could influence far more than cancer care itself.

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its ...

Moderna shares jumped this week after the company announced encouraging results from a late-stage melanoma trial.

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer ...

The U.S. national debt has surpassed $40 trillion for the first time, marking a staggering new milestone in the country’s ...

Merck and Moderna said the good results mark the first successful phase 3 trial for an mRNA-based cancer treatment of this kind. The trial results, however, are yet to be published, and the drug will ...